Showing results (11-20 of 73) with videos related to
Sort By:
Pageof 8
Expert Review of Anticancer Therapy|October 6, 2006
Capecitabine-docetaxel combination treatmentJulia Mandelblat, Tayyaba Bashir, Daniel R BudmanCancer Investigation|August 7, 2003
The androgen receptor: structure, mutations, and antiandrogensSamit Hirawat, Daniel R Budman, Willi KreisBreast Cancer Research and Treatment|September 28, 2006
Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitroDaniel R Budman, Julia Tai, Anthony CalabroAnti-Cancer Drugs|November 20, 2002
Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitroDaniel R Budman, Anthony Calabro, Willi KreisAnnals of Hematology|March 16, 2013
The evolving use of arsenic in pharmacotherapy of malignant diseaseAthena Kritharis, Thomas P Bradley, Daniel R BudmanMolecular Medicine (Cambridge, Mass.)|December 1, 2012
Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancerMyra F Barginear, Veena John, Daniel R BudmanFuture Oncology (London, England)|March 30, 2016
Immune checkpoint inhibitors in lung cancer: past, present and futureNagashree Seetharamu, Daniel R Budman, Kevin M SullivanCritical Reviews in Oncology/Hematology|June 13, 2013
P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potencyIuliana Shapira, Annette Lee, Reena Vora, et al.Molecular Medicine (Cambridge, Mass.)|September 26, 2018
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeuticsKarie Runcie, Daniel R Budman, Veena John, et al.Investigational New Drugs|June 10, 2010
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell linesDaniel R Budman, Julia Tai, Anthony Calabro, et al.Pageof 8